AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative - Buprenorphine & Diversion: The Vermont Regulatory Environment.

Dartmouth Health Continuing Education for Professionals Home, AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative - Buprenorphine & Diversion: The Vermont Regulatory Environment., 1/1/2022 8:00:00 AM - 1/1/2025 8:00:00 AM, This series is designed to increase treatment capacity for opioid use disorders by training more prescribers to be able to treat substance or opioid use disorders.

Content Includes:

• Regulatory board’s perspective on buprenorphine prescribing & diversion control
• FAQ regarding legal and regulatory issues related to MAT and a prescriber’s role in diversion control
• COVID-19 State of Emergency adjustments to laws and regulations of interest to medical professionals who prescribe buprenorphine and how they may relate to diversion control.

Presenter
David Herlihy, JD is the Executive Director of the Vermont Board of Medical Practice. Over the past 25 years he has served Vermont as Commissioner of the Vermont Department of Human Resources, General Counsel for Human Resources, and as an Assistant Attorney General. He recently completed over 30 years’ active and reserve military service with the Vermont Army National Guard and United States Navy.

Learning Outcome(s)
Participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.

Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**. 

* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).

** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Bibliographic Resources

Vermont Board of Medical Practice. Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. 2013; https://www.healthvermont.gov/sites/default/files/documents/2016/12/BMP_Policies_Opioid%20Pain%20Policy%2004022014.pdf. Accessed May 25, 2021.

Vermont Board of Medical Practice. Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. 2013; https://www.healthvermont.gov/sites/default/files/documents/2016/12/BMP_Policies_Data%202000%20Policy%20with%20Intro%20and%20Refs%2006062014.pdf. Accessed May 25, 2021.

Vermont Statues Annotated. Vermont Prescription Monitoring System Rule. 2016; https://www.healthvermont.gov/sites/default/files/documents/pdf/REG_vpms-20170701.pdf. Accessed May 25, 2021.

Vermont Statues Annotated. 18 V.S.A. § 4223.  https://legislature.vermont.gov/statutes/section/18/084/04223. Accessed May 25, 2021.

Code of Federal Regulations. 45 CFR 164.512. 2004; https://www.govinfo.gov/app/details/CFR-2004-title45-vol1/CFR-2004-title45-vol1-sec164-512. Accessed May 25, 2021.

Substance Abuse and Mental Health Services Administration. Frequently Asked Questions (FAQs) and Fact Sheets regarding the Substance Abuse Confidentiality Regulations.  https://www.samhsa.gov/about-us/who-we-are/laws-regulations/confidentiality-regulations-faqs. Accessed May 25, 2021.

Code of Federal Regulations. 42 C.F.R. § 2.11. 2007; https://www.govinfo.gov/app/details/CFR-2007-title42-vol1/CFR-2007-title42-vol1-sec2-11. Accessed May 25, 2021.